ATE281162T1 - Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose - Google Patents

Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose

Info

Publication number
ATE281162T1
ATE281162T1 AT99936702T AT99936702T ATE281162T1 AT E281162 T1 ATE281162 T1 AT E281162T1 AT 99936702 T AT99936702 T AT 99936702T AT 99936702 T AT99936702 T AT 99936702T AT E281162 T1 ATE281162 T1 AT E281162T1
Authority
AT
Austria
Prior art keywords
lateral sclerosis
amyotrophic lateral
treatment
production
medicinal product
Prior art date
Application number
AT99936702T
Other languages
English (en)
Inventor
Yves Christen
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of ATE281162T1 publication Critical patent/ATE281162T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT99936702T 1998-08-07 1999-08-06 Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose ATE281162T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810187A FR2782008B1 (fr) 1998-08-07 1998-08-07 Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique
PCT/FR1999/001948 WO2000007592A1 (fr) 1998-08-07 1999-08-06 Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique

Publications (1)

Publication Number Publication Date
ATE281162T1 true ATE281162T1 (de) 2004-11-15

Family

ID=9529516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99936702T ATE281162T1 (de) 1998-08-07 1999-08-06 Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose

Country Status (12)

Country Link
US (1) US6524629B1 (de)
EP (1) EP1102586B1 (de)
JP (1) JP4510289B2 (de)
AT (1) ATE281162T1 (de)
AU (1) AU5170499A (de)
CA (1) CA2340021C (de)
DE (1) DE69921662T2 (de)
ES (1) ES2230873T3 (de)
FR (1) FR2782008B1 (de)
NO (1) NO327733B1 (de)
PT (1) PT1102586E (de)
WO (1) WO2000007592A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2785808B1 (fr) * 1998-11-13 2002-12-06 Aventis Laboratoire Association riluzole et alpha-tocopherol
FR2827518B1 (fr) * 2001-07-17 2005-07-08 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie
JP4528490B2 (ja) * 2002-06-25 2010-08-18 和光化学株式会社 ギンコライド−aを含有する抗不安剤
WO2004074024A2 (en) 2003-02-19 2004-09-02 Pilkington North America, Inc. Powered slider drive interface and drive assembly
CA2523242A1 (en) * 2003-05-02 2004-11-18 Georgetown University Ginkgo biloba extract as a treatment for therapeutic induced neurotoxicity
WO2006004386A1 (es) * 2004-07-02 2006-01-12 Rojas Castaneda Patricia Uso de un extracto del ginkgo biloba para preparar una medicina para tratar la enfermedad de parkinson
WO2007041611A2 (en) * 2005-09-30 2007-04-12 Kinemed, Inc. Microtubule synthesis as a biomarker
AU2007204991A1 (en) * 2006-01-05 2007-07-19 Kinemed, Inc. Compositions and methods of treatment using modulators of motonueron diseases
FR2904222A1 (fr) * 2006-07-27 2008-02-01 Sod Conseils Rech Applic Utilisation d4extraits de ginkgo biloba pour le traitement de maladies mitochondriales
US20110076236A1 (en) * 2008-05-21 2011-03-31 Kinemed, Inc. Compositions and methods of treatment using modulators of motoneuron diseases
GB0922064D0 (en) 2009-12-17 2010-02-03 Pilkington Group Ltd Soda lime silica glass composition
WO2013108926A1 (en) * 2012-01-17 2013-07-25 Kyoto University Prophylactic and therapeutic drug for amyotrophic lateral sclerosis and method of screening therefor
WO2016114655A1 (en) * 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
WO2017065602A1 (en) * 2015-10-13 2017-04-20 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
CN108096243B (zh) * 2017-11-24 2020-05-29 江苏康缘药业股份有限公司 银杏内酯组合物的医药用途
CN110893183A (zh) * 2018-09-13 2020-03-20 成都百裕制药股份有限公司 银杏萜内酯在制备预防、缓解或治疗肌萎缩侧索硬化药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338995A1 (de) * 1983-10-27 1985-05-09 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Bilobalid enthaltende arzneimittel
DE3940094A1 (de) * 1989-12-04 1991-06-06 Montana Ltd Wirkstoffkonzentrate und neue wirkstoff-kombinationen aus blaettern von ginkgo biloba, ein verfahren zu ihrer herstellung und die wirkstoff-konzentrate bzw. die wirkstoff-kombinationen enthaltenden arzneimittel
DE4328374A1 (de) * 1993-08-24 1995-03-02 Deinlein Kalb Hans Neue Verwendung eines Extraktes aus den Blättern von Ginkgo biloba
KR100472793B1 (ko) * 1995-10-26 2005-06-16 사노피-신델라보 근위축성측삭경화증치료용약제를제조하기위한1-(2-나프트-2-일에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6-테트라히드로피리딘의용도

Also Published As

Publication number Publication date
JP4510289B2 (ja) 2010-07-21
DE69921662D1 (de) 2004-12-09
CA2340021A1 (fr) 2000-02-17
JP2002522387A (ja) 2002-07-23
EP1102586A1 (de) 2001-05-30
FR2782008A1 (fr) 2000-02-11
DE69921662T2 (de) 2005-10-20
ES2230873T3 (es) 2005-05-01
US6524629B1 (en) 2003-02-25
EP1102586B1 (de) 2004-11-03
PT1102586E (pt) 2005-02-28
CA2340021C (fr) 2009-09-15
NO20010627L (no) 2001-02-06
AU5170499A (en) 2000-02-28
WO2000007592A1 (fr) 2000-02-17
FR2782008B1 (fr) 2003-04-25
NO327733B1 (no) 2009-09-14
NO20010627D0 (no) 2001-02-06

Similar Documents

Publication Publication Date Title
ATE281162T1 (de) Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ATE120961T1 (de) Konzentrate von aktiven verbindungen und kombinationen von aktiven verbindungen, ihre verfahren zur herstellung und arzneimittel, die die konzentrate oder die kombinationen enthalten.
ATE299022T1 (de) Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE330593T1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
DE59410052D1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
ATE139445T1 (de) Verwendung von zinkionen zur behandlung der periodontitis
WO2001030335A3 (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
ATE219670T1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
ATE274349T1 (de) Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
DE60002226D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l-carnitin derivate und ginkgo biloba extrakte
DE60206280D1 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
DE69423577D1 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
DE69805096D1 (de) Verwendung von ginkgo biloba extrakten zur herstellung eines medikaments
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
EP0224596A4 (de) Verwendung von aus Schisandrae Fructus extrahierten Dibenzocyclooctadien-Lignanen zur Herstellung eines Arzneimittels für die Behandlung von Leberschwäche.
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69610045D1 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
DE69009989D1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
ATE229803T1 (de) Verwendung eines flavonoid enthaltenden extraktes der planze euphorbia prostrata zur herstellung eines medikamentes zur behandlung von anoraktalen oder kolonbeschwerden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1102586

Country of ref document: EP

EEIH Change in the person of patent owner